Budke B - Search Results

1

Dual and Opposite Effects of hRAD51 Chemical Modulation on HIV-1 Integration.

Thierry S, Benleulmi MS, Sinzelle L, Thierry E, Calmels C, Chaignepain S, Waffo-Teguo P, Merillon JM, Budke B, Pasquet JM, Litvak S, Ciuffi A, Sung P, Connell P, Hauber I, Hauber J, Andreola ML, Delelis O, Parissi V. Thierry S, et al. Among authors: budke b. Chem Biol. 2015 Jun 18;22(6):712-23. doi: 10.1016/j.chembiol.2015.04.020. Epub 2015 Jun 4. Chem Biol. 2015. PMID: 26051216 Free PMC article.

2

An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity.

Budke B, Kalin JH, Pawlowski M, Zelivianskaia AS, Wu M, Kozikowski AP, Connell PP. Budke B, et al. J Med Chem. 2013 Jan 10;56(1):254-63. doi: 10.1021/jm301565b. Epub 2012 Dec 26. J Med Chem. 2013. PMID: 23231413 Free PMC article.

3

Real-time solution measurement of RAD51- and RecA-mediated strand assimilation without background annealing.

Budke B, Chan YL, Bishop DK, Connell PP. Budke B, et al. Nucleic Acids Res. 2013 Jul;41(13):e130. doi: 10.1093/nar/gkt362. Epub 2013 May 10. Nucleic Acids Res. 2013. PMID: 23666628 Free PMC article.

4

Recent Developments Using Small Molecules to Target RAD51: How to Best Modulate RAD51 for Anticancer Therapy?

Budke B, Lv W, Kozikowski AP, Connell PP. Budke B, et al. ChemMedChem. 2016 Nov 21;11(22):2468-2473. doi: 10.1002/cmdc.201600426. Epub 2016 Oct 26. ChemMedChem. 2016. PMID: 27781374 Free PMC article. Review.

5

Optimization of Drug Candidates That Inhibit the D-Loop Activity of RAD51.

Budke B, Tueckmantel W, Miles K, Kozikowski AP, Connell PP. Budke B, et al. ChemMedChem. 2019 May 17;14(10):1031-1040. doi: 10.1002/cmdc.201900075. Epub 2019 Apr 17. ChemMedChem. 2019. PMID: 30957434 Free PMC article.

6

RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells.

Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, Stark JM, Kozikowski AP, Bishop DK, Connell PP. Budke B, et al. Nucleic Acids Res. 2012 Aug;40(15):7347-57. doi: 10.1093/nar/gks353. Epub 2012 May 9. Nucleic Acids Res. 2012. PMID: 22573178 Free PMC article.

7

Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51.

Lv W, Budke B, Pawlowski M, Connell PP, Kozikowski AP. Lv W, et al. Among authors: budke b. J Med Chem. 2016 May 26;59(10):4511-25. doi: 10.1021/acs.jmedchem.5b01762. Epub 2016 Apr 21. J Med Chem. 2016. PMID: 27049177 Free PMC article.

8

[No title available]

[No authors listed] [No authors listed] PMID: 34700966

9

DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy.

Pitroda SP, Pashtan IM, Logan HL, Budke B, Darga TE, Weichselbaum RR, Connell PP. Pitroda SP, et al. Among authors: budke b. Sci Transl Med. 2014 Mar 26;6(229):229ra42. doi: 10.1126/scitranslmed.3008291. Sci Transl Med. 2014. PMID: 24670686 Free PMC article.

10

The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors.

Mason JM, Logan HL, Budke B, Wu M, Pawlowski M, Weichselbaum RR, Kozikowski AP, Bishop DK, Connell PP. Mason JM, et al. Among authors: budke b. Cancer Res. 2014 Jul 1;74(13):3546-55. doi: 10.1158/0008-5472.CAN-13-3220. Epub 2014 Apr 21. Cancer Res. 2014. PMID: 24753542 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters